You Can't Negotiate Your Way to Lower Claims

Here's the uncomfortable part of this renewal season: the number on your renewal letter is not the problem. It's the receipt.

Depending on which survey you read, employers are looking at a 2026 medical trend somewhere between 6.5% and 10% — Mercer puts it at 6.5% *after* cost-cutting measures (closer to 9% if you do nothing), Business Group on Health at a 9% median, Aon at 9.5%, the International Foundation at 10%. Pick your source; they all point the same direction. This is the fourth straight year of near-double-digit increases following a decade that averaged about 3%. Average cost per employee is now clearing $18,000.

Most leadership teams respond the way they always have. They negotiate harder. They shift more cost to employees. And they walk into next year's renewal genuinely surprised it happened again.

I want to be direct about why.

## Negotiation works on price. It does nothing to claims.

A good broker can compress administrative spread, sharpen your stop-loss, and tighten network discounts. That's real, and it's worth doing. But none of it touches the thing actually generating your cost: the claims your population produces.

You cannot negotiate a cancer diagnosis into a lower number. You cannot negotiate down an avoidable ER visit, a preventable readmission, or a chronic condition that went unmanaged until it became a catastrophic claim. By the time a claim is on the ledger, the leverage is gone. Negotiation moves the cost around the table. It never takes the cost off the table.

This year makes the point sharply. Prescription drug spend jumped 9.4% — the steepest increase in a decade — driven heavily by GLP-1s. Cancer and complex chronic conditions are climbing. Those are claims problems. No renewal conversation solves a claims problem.

## Cost-shifting isn't a strategy. It's a transfer.

The second reflex is to raise deductibles and copays. In 2026, 59% of employers are doing exactly that — up from 44% just two years ago.

Understand what that actually does. It doesn't reduce spend; it relocates it onto your employees' paychecks, at roughly 6–7% more out of their pockets. And it carries a hidden bill: when people delay care because it's expensive, small problems become big claims. You don't avoid the cost. You defer it, with interest, and you erode the benefit your best people stay for while you do it.

If your only two moves are "negotiate the rate" and "shift it to staff," you are managing the symptom and feeding the disease.

## The only durable lever is the claim itself.

There is exactly one way to bend this curve instead of riding it: reduce the avoidable and high-cost claims before they're incurred. That is a clinical problem, not a procurement problem — which is precisely why the procurement playbook keeps failing against it.

This is the entire premise of how we built Apex Health. We don't replace your carrier, your broker, or your plan. We add a physician-led clinical layer on top of the stack you already run, organized around a simple sequence — **Predict, Care, Integrate:**

- **Predict.** AI risk stratification reads your population and surfaces rising-risk members *before* they generate a high-cost event — instead of finding out at claim time.

- **Care.** 24/7 ER-trained virtual primary and urgent care, remote patient monitoring for chronic conditions, and integrated care management intercept those events. Skip the ER for non-emergencies; call 911 for true emergencies.

- **Integrate.** All of it layers over your existing carrier and broker relationships. Nothing to rip out.

In typical client cohorts that produces up to a 35% reduction in avoidable claims, roughly 8.5x ER diversion, and about a 45% reduction in readmissions. Those are typical ranges, not guarantees — and the only ones that matter, because they hit the claim, not the invoice.

## The reframe your CFO is waiting for

For a finance leader, this stops being a benefits line and becomes a margin lever. Apex PMPM fees are deductible as ordinary and necessary business expenses under IRS §162; §105 HRA structuring can extend the treatment further, which is worth modeling with your own tax counsel before you bank on it. Net those fees against the claims reduction and the result isn't "another vendor." It's a pre-tax, EBITDA-positive operating decision.

That's the conversation worth having — not "how do we survive this renewal," but "how do we make next year's renewal smaller because the claims behind it shrank."

## Where this leaves you

You can keep negotiating a number that was decided long before the renewal letter arrived. Or you can go after the claims that wrote it.

One of those is a strategy. The other is a receipt.

---

**If your 2026 renewal landed harder than you budgeted, let's pressure-test where your claims trend is actually coming from — and what a clinical layer could bend.** Message me directly, or reach the team at **scottp@aichealth.net** to walk through your population. No pitch deck. A claims conversation.

*Apex Health — the physician-led platform for employer healthcare cost reduction.*

`#EmployeeBenefits #SelfFunded #HealthcareCosts #CFO #BenefitsStrategy #PopulationHealth`